ClinicalTrials.gg
RecruitingNCT04192344Updated Nov 9, 2026

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

A Phase 1 interventional study of ABSK021 in Neoplasms and Tenosynovial Giant Cell Tumor, sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 17 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionGiant Cell Tumor of Tendon SheathRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Giant Cell Tumor of Tendon Sheath
Why
  1. The study's listed conditions name Giant Cell Tumor of Tendon Sheath, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 9 months later.
Updated Nov 9, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
276
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.

Read the detailed description

The study will start with a dose escalation part of single-agent ABSK021 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability. The expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

02

Conditions studied

  • Neoplasms
  • Tenosynovial Giant Cell Tumor

Browse trials for

Keywords

  • Tenosynovial Giant Cell Tumor
  • TGCT
  • Solid tumors
03

In context

Giant Cell Tumor of Tendon Sheath Reclassified

22 studies on the registry are indexed under Giant Cell Tumor of Tendon Sheath; 5 are open to participants now.

This study's planned enrollment of 276 is above the median of 34 across 20 interventional studies indexed under Giant Cell Tumor of Tendon Sheath.

Browse Giant Cell Tumor of Tendon Sheath studies →

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Compared within Giant Cell Tumor of Tendon Sheath, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed solid tumors that have progressed on or intolerant to standard therapy or whom no standard therapy exists
  • (electrocorticogram) performance status 0\~1
  • ≥ 3 months
  • Adequate organ function and bone marrow function

For patients with tenosynovial giant cell tumor (TGCT) :

  1. A diagnosis of TGCT [i ncluding pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT TS) (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pathologist,and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a multi disciplinary tumor board);
  2. as defined by 1.1 (except that a minimal size of 2 cm is required), assessed from MRI scans;
  3. Others

For Adolescent Cohort (China only):

  1. Patient and/or legally acceptable representative should understand, sign, and date the written voluntary form prior to screening.
  2. Adolescents≥ 12 years of age and \< 18 years at the time of informed consent.
  3. Body weight ≥ 40kg.
  4. A diagnosis of TGCT [including pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT-TS)] (i) that has been histologically confirmed either by local laboratory, and (ii) unresectable, defined as confirmed by assessment by at least two clinical experts (including at least one independent expert who is not part of the trial conduct), meeting one of the following 2 requirements: ①located in a complex anatomical site, is extensively invasive, and cannot be completely resected; ②surgical operation may cause dysfunction or serious complications.
  5. Measurable disease as defined by RECIST v1.1 (with at least 1 lesion ≥ 2 cm is required), assessed by MRI scans in local site prior to dosing.
  6. Others

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to any component of the drug product Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating factor 1 receptor) pathway inhibitors
  • Known additional that is progressing or required active treatment within 3 years of the first dose of study treatment
  • Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication
  • Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment)
  • Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence
  • Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤2 severity ( v5.0) with the exception of alopecia and vitiligo
  • Prior as anti-cancer therapy within a minimum of 2 weeks of the first dose of study drug
  • Concomitant use of strong inhibitors or inducers of
  • Active central nervous system (CNS)
  • Impaired cardiac function or cardiac disease
  • Patients with Gilbert's Syndrome or other underlying conditions that may lead to a greater likelihood of developing LFT(liver function test) abnormalities during the study
  • Known or active , or active infection
  • /uncontrolled ascites or pleural effusion
  • Pregnant or nursing

For patients with tenosynovial giant cell tumor (TGCT) :

  1. Known allergy or hypersensitivity to any component of the investigational drug product
  2. For expansion part, previous treatment with CSF 1/CSF 1R pathway inhibitors (not applicable for TGCT patients in US)
  3. Others

For Adolescent Cohort (China only):

  1. Known allergy or hypersensitivity to any component of the investigational drug product.
  2. Previous treatment with highly selective inhibitors targeting CSF-1/CSF-1R prior to first dosing. However, patients who have received prior treatment with multi-kinase inhibitors that include the CSF-1/CSF-1R pathway are allowed, such as Imatinib and Nilotinib.
  3. Know additional malignancy that required active treatment and may affect the patient's participation in the study or affect the outcome of the study as assessed by the Investigator. Exceptions include cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and other carcinoma in situ.
  4. Others
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    ABSK021

    Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by"3+3" escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles.

    Drug: ABSK021

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    DLT(dose-limiting toxicity)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Incidence and Severity of AEs

    Adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. PFS

    Progression-Free Survival (PFS)

    Time frame: From date of enrollment until the date of first documented progression or death, assessed up to 12 months

  2. DoR

    Duration of Response (DoR)

    Time frame: From date of enrollment until the date of first documented progression or death, assessed up to 12 months

  3. DCR

    Disease Control Rate (DCR)

    Time frame: 24 weeks post-dose

  4. Cmax

    The peak plasma concentration of a drug after administration

    Time frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose

  5. tmax

    Time to reach Cmax

    Time frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose

  6. Bioavailability

    The systemically available fraction of a drug

    Time frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose

  7. Elimination half-life

    The time required for the concentration of the drug to reach half of its original value

    Time frame: Pre-dose and multiple timepoints (up to 72 hours) post-dose

07

Study locations

3 of 17 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2020 (actual). Primary completion is estimated for Dec 2031, 143 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Dec 2026 → Dec 2031 and completion Dec 2026 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2019
First posted
Dec 10, 2019
StartActual
Jan 20, 2020
Primary completionEst.
Dec 31, 2031was Dec 2026
CompletionEst.
Dec 31, 2031was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now active, not recruiting)
Show 2 sites
  • The First Affiliated Hospital of Sun Yat-sen University · Guangdong, ChinaRecruiting→Active, not recruiting
  • Xi'an Hong Hui Hospital · Xian, ChinaRecruiting→Active, not recruiting
Nov 9, 2026
Primary completion
Dec 31, 2026→Dec 31, 2031
Nov 9, 2026
Study completion
Dec 31, 2026→Dec 31, 2031
Nov 9, 2026
Eligibility
Minimum age 18 Years→12 Years; 7 inclusion criteria added; 5 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • AddedFor Adolescent Cohort (China only):
  • AddedPatient and/or legally acceptable representative should understand, sign, and date the written voluntary informed consent form prior to screening.
  • AddedAdolescents≥ 12 years of age and < 18 years at the time of informed consent.
  • AddedBody weight ≥ 40kg.
  • AddedA diagnosis of TGCT [including pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT-TS)] (i) that has been histologically confirmed either by local laboratory, and (ii) unresectable, defined as confirmed by assessment by at least two clinical experts (including at least one independent expert who is not part of the trial conduct), meeting one of the following 2 requirements: ①located in a complex anatomical site, is extensively invasive, and cannot be completely resected; ②surgical operation may cause dysfunction or serious complications.
  • AddedMeasurable disease as defined by RECIST v1.1 (with at least 1 lesion ≥ 2 cm is required), assessed by MRI scans in local site prior to dosing.
  • AddedOthers
Exclusion criteria
  • AddedFor Adolescent Cohort (China only):
  • AddedKnown allergy or hypersensitivity to any component of the investigational drug product.
  • AddedPrevious treatment with highly selective inhibitors targeting CSF-1/CSF-1R prior to first dosing. However, patients who have received prior treatment with multi-kinase inhibitors that include the CSF-1/CSF-1R pathway are allowed, such as Imatinib and Nilotinib.
  • AddedKnow additional malignancy that required active treatment and may affect the patient's participation in the study or affect the outcome of the study as assessed by the Investigator. Exceptions include cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and other carcinoma in situ.
  • AddedOthers
Nov 9, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • The First Affiliated Hospital of Sun Yat-sen University · Guangdong, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Xi'an Hong Hui Hospital · Xian, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • The First Affiliated Hospital of Sun Yat-sen University · Guangdong, ChinaRecruiting→Active, not recruiting
    • Xi'an Hong Hui Hospital · Xian, ChinaRecruiting→Active, not recruiting
    Primary completion Dec 31, 2026→Dec 31, 2031
    Study completion Dec 31, 2026→Dec 31, 2031
    Eligibility Minimum age 18 Years→12 Years; 7 inclusion criteria added; 5 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • AddedFor Adolescent Cohort (China only):
    • AddedPatient and/or legally acceptable representative should understand, sign, and date the written voluntary informed consent form prior to screening.
    • AddedAdolescents≥ 12 years of age and < 18 years at the time of informed consent.
    • AddedBody weight ≥ 40kg.
    • AddedA diagnosis of TGCT [including pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT-TS)] (i) that has been histologically confirmed either by local laboratory, and (ii) unresectable, defined as confirmed by assessment by at least two clinical experts (including at least one independent expert who is not part of the trial conduct), meeting one of the following 2 requirements: ①located in a complex anatomical site, is extensively invasive, and cannot be completely resected; ②surgical operation may cause dysfunction or serious complications.
    • AddedMeasurable disease as defined by RECIST v1.1 (with at least 1 lesion ≥ 2 cm is required), assessed by MRI scans in local site prior to dosing.
    • AddedOthers
    Exclusion criteria
    • AddedFor Adolescent Cohort (China only):
    • AddedKnown allergy or hypersensitivity to any component of the investigational drug product.
    • AddedPrevious treatment with highly selective inhibitors targeting CSF-1/CSF-1R prior to first dosing. However, patients who have received prior treatment with multi-kinase inhibitors that include the CSF-1/CSF-1R pathway are allowed, such as Imatinib and Nilotinib.
    • AddedKnow additional malignancy that required active treatment and may affect the patient's participation in the study or affect the outcome of the study as assessed by the Investigator. Exceptions include cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and other carcinoma in situ.
    • AddedOthers
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • The First Affiliated Hospital of Sun Yat-sen University · Guangdong, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Xi'an Hong Hui Hospital · Xian, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04192344
Responsible party
Sponsor
First posted
Dec 10, 2019
Start date
Jan 20, 2020
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

YUAN LU
Contact
clinical@abbisko.cn
+86-21-68910052
Siqing Fu, MD
Contact
siqingfu@mdanderson.org
(713)792-4318
Siqing Fu, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimicotinib

Start the discussion